Skip to main content

Denali Therapeutics

Denali Therapeutics Inc is an American clinical-stage biopharmaceutical company developing therapies for neurodegenerative and lysosomal storage diseases. The company utilizes its proprietary Transport Vehicle technology platform to engineer therapeutic molecules that cross the blood-brain barrier for CNS targets. Principal revenues are generated through strategic research collaborations, licensing agreements, and milestone payments from global biopharmaceutical partners. Core end markets serve neurology clinical centers, lysosomal storage disease clinics, and specialized rare disease treatment facilities. Denali Therapeutics holds a pioneering position in brain delivery technology and neurodegenerative disease drug development. The company is headquartered in South San Francisco, California, and its common stock trades on the Nasdaq Global Select Market.

8 of the funds FundTelligence covers report a position in Denali Therapeutics.

Legal name
Denali Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
8
Exposure themes
Ageing & Longevity, Age-Related Disease, Neurodegeneration

Funds holding Denali Therapeutics

Loading...